Haemonetics Co. (NYSE:HAE) Holdings Increased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans increased its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 29.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,100,183 shares of the medical instruments supplier's stock after acquiring an additional 250,833 shares during the period. Thrivent Financial for Lutherans owned about 2.15% of Haemonetics worth $88,433,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Quarry LP purchased a new position in shares of Haemonetics during the 2nd quarter worth approximately $39,000. Covestor Ltd lifted its position in Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 438 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in Haemonetics during the second quarter valued at about $82,000. Canada Pension Plan Investment Board bought a new stake in Haemonetics during the second quarter valued at about $83,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Haemonetics in the first quarter worth about $86,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Trading Down 1.2 %

HAE stock traded down $1.07 on Monday, hitting $88.15. 553,605 shares of the company were exchanged, compared to its average volume of 555,770. Haemonetics Co. has a twelve month low of $70.25 and a twelve month high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The business's fifty day moving average is $77.55 and its two-hundred day moving average is $82.62. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 37.02, a price-to-earnings-growth ratio of 1.39 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business's quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.99 earnings per share. As a group, research analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. BTIG Research started coverage on Haemonetics in a research report on Tuesday, September 10th. They set a "buy" rating and a $112.00 target price for the company. Raymond James raised Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 target price on the stock in a research report on Friday, November 8th. JMP Securities reaffirmed a "market outperform" rating and issued a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Bank of America started coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They set a "neutral" rating and a $85.00 target price on the stock. Finally, Barrington Research reiterated an "outperform" rating and issued a $108.00 price objective on shares of Haemonetics in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of "Moderate Buy" and a consensus target price of $107.88.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.